Gilead Sciences (GILD): Trial Suspension Impacts Sentiment More Than Revenue - Leerink

September 22, 2016 8:25 AM EDT
Get Alerts GILD Hot Sheet
Price: $74.29 -0.03%

Rating Summary:
    23 Buy, 11 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade GILD Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Leerink Partners analyst, Geoffrey Porges, reiterated his Outperform rating on shares of Gilead Sciences (NASDAQ: GILD) after the company announced the suspension of its phase 2/3 for GS-5745. This is GILD's anti-matrix metalloproteinase 9 (MMP9) anti-body for the treatment of ulcerative colitis (UC). The company made this decision after the data monitoring committee recommended termination, with the treatment failing to demonstrate any signal of efficacy in an 8-week induction interim analysis of the first 150 patients from a 1,600-patient phase III trial.

The company noted it is proceeding with its ongoing phase 3 in gastric cancer (primary completion date January 2019); another phase 2 in gastric cancer with nivolumab (September 2018); and phase 2 trials in Crohn’s (October 2016), rheumatoid arthritis (March 2018), and cystic fibrosis (December 2018).

The analyst views other MMP9 trials as risky. There is little revenue downside but they represent a blow to R&D prospects as well as investor sentiment. No change to the price target of $112.

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $81.70 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, FDA

Add Your Comment